Factory 99% Dabrafenib Powder CAS 1195765-45-7 Chemical Intermediate Dabrafenib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A787
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Dabrafenib
• CAS: 1195765-45-7
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Dabrafenib
Appearance	White Powder
CAS NO.	1195765-45-7
Storage	Keep in a cool, dry, dark location

 

Dabrafenib is an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. It has the chemical formula C23H20F3N5O2S2 and CAS number 1195765-45-7.

 

1. Melanoma Treatment: Dabrafenib is primarily used for the treatment of metastatic melanoma and melanoma that is not amenable to surgical resection. It is particularly effective in patients with BRAF V600E mutations.
2. Combination Therapy: In combination with trametinib, dabrafenib is approved for the treatment of BRAF V600E mutation-positive non-small cell lung cancer (NSCLC). This combination therapy enhances the antitumor effect by targeting both BRAF and MEK, key components of the MAPK signaling pathway.
3. Expanded Use in Oncology: Additionally, dabrafenib has been approved for the treatment of anaplastic thyroid cancer (ATC) caused by BRAF V600E mutations, demonstrating its versatility in oncology.

1. BRAF Inhibition: Dabrafenib selectively binds to and inhibits the activity of mutated BRAF protein, which is often constitutively activated due to gene mutations. This inhibition disrupts the MAPK/ERK signaling pathway, a critical driver of cell growth and proliferation in cancer cells.
2. Antitumor Activity: By inhibiting BRAF, dabrafenib slows the growth and division of cancer cells containing mutated BRAF genes. This leads to a reduction in tumor size and an improvement in patient outcomes.
3. Enhanced Efficacy in Combination: When combined with trametinib, dabrafenib exhibits enhanced antitumor activity by blocking both BRAF and MEK, two key nodes in the MAPK signaling pathway. This combination therapy is more effective than dabrafenib alone in certain cancer types.